NASDAQ · BLRX
Healthcare · Biotechnology
$2.55
Up+$0.02 (+0.76%)
Updated Sep 10, 2026, 10:02 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BLRX closed at $2.55 after 20 trading sessions, down 5.20% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $2.59 | $2.59 | $2.53 | $2.55 | 7.74K |
| Sep 8, 2026 | $2.78 | $2.78 | $2.55 | $2.59 | 19.85K |
| Sep 4, 2026 | $2.72 | $2.72 | $2.55 | $2.67 | 27.94K |
| Sep 3, 2026 | $2.65 | $2.75 | $2.60 | $2.69 | 22.33K |
| Sep 2, 2026 | $2.80 | $2.80 | $2.57 | $2.74 | 28.34K |
| Sep 1, 2026 | $2.89 | $2.89 | $2.60 | $2.76 | 69.27K |
| Aug 31, 2026 | $2.90 | $2.9069 | $2.55 | $2.80 | 214.85K |
| Aug 28, 2026 | $2.56 | $2.72 | $2.56 | $2.60 | 49K |
| Aug 27, 2026 | $2.85 | $2.85 | $2.76 | $2.76 | 2.27K |
| Aug 26, 2026 | $2.91 | $3.0304 | $2.65 | $2.70 | 13.07K |
| Aug 25, 2026 | $3.0309 | $3.0309 | $2.6601 | $2.85 | 7.04K |
| Aug 24, 2026 | $2.8901 | $3.023 | $2.77 | $3.00 | 5.13K |
| Aug 21, 2026 | $2.86 | $3.10 | $2.7999 | $2.81 | 2.69K |
| Aug 20, 2026 | $2.96 | $3.00 | $2.76 | $2.76 | 4.27K |
| Aug 19, 2026 | $2.73 | $2.93 | $2.73 | $2.93 | 2.41K |
| Aug 18, 2026 | $2.67 | $2.85 | $2.67 | $2.85 | 20.4K |
| Aug 17, 2026 | $2.76 | $2.86 | $2.6047 | $2.64 | 19.7K |
| Aug 14, 2026 | $2.70 | $2.76 | $2.69 | $2.76 | 3.08K |
| Aug 13, 2026 | $2.69 | $2.87 | $2.65 | $2.7187 | 4.89K |
| Aug 12, 2026 | $2.72 | $3.0016 | $2.6877 | $2.69 | 11.29K |
The latest Smart Investors Daily articles mentioning BLRX.
BLRX research
Company profile and research snapshot.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 16, 2020 | HC Wainwright & Co. | Buy | — |
| Aug 4, 2017 | Oppenheimer | Outperform | — |
| May 18, 2017 | Maxim Group | Buy | — |
| Feb 13, 2017 | Rodman & Renshaw | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 1, 2026
By John Vandermosten, CFA NASDAQ: BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ: BLRX) reported second quarter 2026 financial and operational results in an August 31 st press release. For the quarter, it produced license revenues of $294,000 and a net loss of $4.3 million. The joint venture (JV) with Hemispherian, which is developing GLIX1, has begun enrolling the second of five
Yahoo · Aug 31, 2026
BioLine Rx reports promising preclinical data for its lead candidate GLIX1 while managing a tight cash position and flat royalty revenue.
SeekingAlpha · Aug 31, 2026
BioLineRx Ltd. (BLRX) Q2 2026 Earnings Call August 31, 2026 8:30 AM EDTCompany ParticipantsPhilip Serlin - Chief Executive OfficerMali Zeevi - Chief...
Yahoo · Aug 31, 2026
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended June 30, 2026, and provided a corporate update.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BLRX.
No results
No recent SID articles mention BLRX.
